The Human Variable: The Leadership Risk Biotech Governance Still Ignores
By Maria Bostock
Biotech is the most honest leadership environment in the world. Science does not soften bad news. Markets do not wait for leaders to feel ready. And the pressure does not lift between a failed trial, a regulatory delay, and a funding conversation that has shifted in tone. It compounds.
That is not a flaw in the sector. It is the condition. And it makes biotech the clearest mirror that leadership has. Because when a leader does not have the inner capacity to hold what the environment asks of them, everyone sees it. The team feels it before they can name it. Decisions slow or swing. Communication fragments. The best people start quietly recalibrating their confidence in the organization above them.
This is not about leadership style or technical capability. It is about something more fundamental. Whether the person at the top of the organization has the inner resource to process what is actually happening, stay steady under sustained pressure, and lead without transmitting the unprocessed weight of it downward.
That resource is leadership capacity. And it is the variable biotech governance still ignores.
What Governance Frameworks Measure And What They Miss
Biotech boards are rigorous. They assess scientific risk, regulatory exposure, capital runway and pipeline breadth. They evaluate bench strength and commercial readiness. What they do not formally assess is whether the leadership function has the inner capacity to perform under the specific and unrelenting conditions this industry generates.
This is not a criticism of boards. It is an observation about what has never been named. Capability gets assessed. Experience gets evaluated. But capacity, the human resource that determines whether a leader can hold complexity without distorting it, process setback without transmitting it, and sustain clarity when the ground is shifting, has been assumed rather than examined.
Neuroscience tells us that assumption is costly. Research by Amy Arnsten at Yale established that sustained exposure to uncertainty and threat impairs function in the prefrontal cortex, the part of the brain responsible for strategic reasoning, nuanced judgement, and long-range thinking. The very faculties a biotech CEO needs most are the first to degrade under chronic pressure. This is not a character issue. It is a physiological one. And it happens invisibly, gradually, and at exactly the moment the organization can least afford it.
Leaders Cannot Steady Their Teams Through Change They Have Not Processed Themselves
This is the line that boards and Chief Human Resource Officers (CHROs) need to sit with. Because in biotech, when a Phase III trial fails, when a Complete Response Letter lands, when a funding round closes harder than expected, the entire organization watches how the leadership team holds that moment. Not what they say. How they hold it.
If the capacity is there, the leader processes the reality, stays grounded, communicates with steadiness and brings the organization with them into what comes next. If it is not, something else transmits. Not always loudly. Often it is a fractured communication, a decision that swings too fast or stalls too long, a tone in the room that tells the team the leader has not yet processed what just happened.
Daniel Kahneman's work on decision-making under pressure maps this precisely. When emotional load is high and the inner resource is depleted, fast reactive thinking overrides the calibrated reasoning that consequential decisions require. Experience and intelligence do not protect against this. Capacity does.
The Scale-Up Inflection Point
The risk is highest at the founder to scale-up transition. This is where biotech loses more leadership ground than it recognizes. A founder who navigated uncertainty brilliantly in a small team must now hold it across layers of management, a broader investor base, and a workforce whose read of the organization flows directly from the steadiness of the leadership above them.
The scientific depth that built the company provides no reserve for this. Research from the Centre for Creative Leadership shows consistently that technically expert leaders, the default pipeline into biotech's senior roles, frequently underestimate how much their effectiveness now depends not on what they know but on what they can hold. In biotech scale-ups that gap surfaces at the worst possible moment. Late-stage trials. Pre-commercialization build. Post-acquisition integration.
Recovery speed matters here in a way that is commercially visible. Organizations whose leaders have the capacity to process setbacks quickly, reorient teams, and restore momentum recover competitive ground faster. Those where leadership uncertainty transmits into the system compound the original setback. The science already asked enough of the organization. Leadership capacity is what determines how much of that cost gets absorbed and how much of it spreads.
Why This Belongs In The Governance Conversation
Susan David's research at Harvard Medical School identifies what she terms emotional rigidity, the tendency to suppress or be overwhelmed by difficult emotional data, as a significant predictor of poor performance under sustained uncertainty. Leaders with greater inner capacity demonstrate more reliable strategic clarity under pressure, stronger ability to process difficult information without distorting it, and more consistent alignment between intent and action when stakes are high.
That is not a coaching outcome. It is a performance condition. And it is either present or it is not.
Boards that take this seriously stop treating leadership capacity as a personal attribute that leaders either have or do not. They start treating it as an organizational variable. Something that can be built, can be depleted, and has direct consequences for decision quality, talent retention, investor confidence, and commercial trajectory.
The question is not whether the leadership team is experienced or capable. It is whether they have the inner resource to hold what this industry asks of them. Continuously. Under sustained pressure. Without it transmitting in the wrong direction.
That is the variable biotech governance still ignores. And in an industry where the margin between a good decision and a reactive one can determine the fate of a programme, ignoring it is a risk that deserves to be on the board agenda.
About The Author:
Maria Bostock is a change leadership specialist with over 25 years leading people through M&A, restructures, and enterprise transformation in large and Fortune 500 organizations including Danaher Life Sciences. An Emotional Agility Practitioner from the first cohort trained by Dr. Susan David at Harvard Medical School and a Fellow of the Chartered Institute of Personnel and Development, Maria works with CHROs, CEOs and boards to build the leadership capacity that sustains organizational performance through complex transformation. She is the creator of Energy-Smart Change Leadership™ and the author of Surfing the Waves of Change.
SUPPORTING RESEARCH REFERENCES
- Arnsten, A.F.T. (2009). Stress signalling pathways that impair prefrontal cortex structure and function. Nature Reviews Neuroscience, 10(6), 410-422.
- David, S. (2016). Emotional Agility: Get Unstuck, Embrace Change, and Thrive in Work and Life. Avery/Penguin.
- Kahneman, D. (2011). Thinking, Fast and Slow. Farrar, Straus and Giroux.
- Rock, D. (2008). SCARF: A brain-based model for collaborating with and influencing others. NeuroLeadership Journal, 1(1), 44-52.
- Centre for Creative Leadership (2019). The Leadership Gap: What Gets in the Way of Great Leadership. CCL Research Report.